Nyrada Inc (ASX:NYR) Full Year Results FY21
Highlights: • Research and development costs of $2.2M as Nyrada’s lead preclinical programs advance (FY2020: $1.4M) • Capital raising program… Read more
Incannex NOTICE OF EXTRAORDINARY GENERAL MEETING
Incannex files registration statement with the SEC for proposed initial public offering in the United States
HTG: VESSEL REDELIVERY SHINES SPOTLIGHT ON TECHNOLOGY
NYR In Vivo Trial Results Show Further Positive Results
Last Friday, Nyrada released further positive results from an animal trial using a mouse model genetically modified to mimic human-like… Read more
ReNerve Shareholder Newsletter August 2021
Some notable highlights : Presentation of ReNerve at the Royal Australian College of Surgeons Annual Scientific Meeting in Melbourne Launch… Read more
Incannex Psi-GAD clinical development overview
Incannex submits HREC proposal and FDA pre-IND meeting request for Psi-GAD psilocybin therapy for Generalised Anxiety Disorder
We wish to draw your attention to an announcement and presentation released by Incannex (ASX:IHL) this week. The company has… Read more
